ARTICLE | Clinical News
EC approves Novartis' rituximab biosimilar Rixathon
August 11, 2017 4:07 PM UTC
In June, Novartis AG (NYSE:NVS; SIX:NOVN) said the European Commission approved Rixathon (GP2013), a biosimilar of Rituxan/MabThera rituximab from Roche (SIX:ROG; OTCQX:RHHBY), for all of MabThera's...